Exploring Anti-RANKL therapy with checkpoint inhibitors in breast cancer

Alexis LeVee, MD, City of Hope, Duarte, CA, discusses the potential synergy between anti-RANKL therapy, such as denosumab, and immune checkpoint inhibitors in breast cancer. Preclinical findings showing enhanced tumor infiltrating lymphocytes, increased CD+ T-cells, and reduced metastases in models combining these therapies. Studies are underway to assess whether this combination improves clinical outcomes, offering insights into its potential to modulate the tumor microenvironment and enhance immune responses in breast cancer. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.